Partners

Cizzle is involved in a number of academic and commercial partnerships that are designed to extend data sets, generate tools and materials and expand the knowledge base from which Cizzle conducts its operations.  Amongst these, are the following commercial organisations:-

During 2010, Cizzle plans to enter into more arrangements with commercial organisations which will bring forward development plans for the diagnostic and biomarker potential for Ciz1 in SCLC and to advance early results in the area of RNAi based therapies.  The Company has investigated the effect of RNAi directed against a specific splice variant of Ciz1 in mouse xenograft  models of SCLC.  Results were extremely promising and initial discussions with interested parties are underway.

If you are interested in knowing more about partnering opportunities, please contact: dawn.coverley@cizzlebiotechnology.co.uk

Investors

In 2006, Cizzle attracted seed-corn financing from the White Rose Technology Seedcorn Fund (WRTSCF) to support research and development activities relating to the Ciz1 gene and its splice variants, as part of a combined drug target/biomarker validation project.

Business development and expansion of research and development activities are ongoing following further investment in early 2008 by WRTSCF and additional investment by The Viking Fund and Yorkshire Cancer Research.

More information about Cizzle can be found here: download

Cizzle Biotech
Heslington Hall, Heslington, York, North Yorkshire, Y010 5DD
UK company 5249093